Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Zurich | OTHER |
| University Hospital, Zürich | OTHER |
Not provided
Not provided
Not provided
Not provided
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| International Hidradenitis Suppurativa Severity Score System (IHS4) | Clinician-assessed measure of hidradenitis suppurativa severity based on the number of inflammatory nodules, abscesses, and draining tunnels; higher scores indicate more severe disease. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Measure | Description | Time Frame |
|---|---|---|
| Hurley Staging System | Clinician-assessed classification of hidradenitis suppurativa severity categorized as Stage I, Stage II, or Stage III. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Sartorius Hidradenitis Suppurativa Severity Score (HSS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient populations across world regions seen for hidradenitis suppurativa.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julia-Tatjana Maul, Prof. Dr. med. | Contact | +41 76 441 51 09 | julia-tatjana.maul@usz.ch | |
| Johannes Didaskalu | Contact | johannes.didaskalu@usz.ch |
| Name | Affiliation | Role |
|---|---|---|
| Julia-Tatjana Maul, Prof. Dr. med. | University of Zurich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Zurich | Recruiting | Zurich | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017497 | Hidradenitis Suppurativa |
| ID | Term |
|---|---|
| D017192 | Skin Diseases, Bacterial |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Clinician-assessed measure of hidradenitis suppurativa severity incorporating lesion counts and anatomical involvement; higher scores indicate more severe disease. |
| Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Physician Global Assessment (PGA) | Clinician-assessed global measure of hidradenitis suppurativa severity on a scale from 0 to 4, with higher scores indicating more severe disease. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Dermatology Life Quality Index (DLQI) | Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Patient-reported Numerical Rating Scale (NRS) for severity of hidradenitis suppurativa | Patient-reported assessment of overall hidradenitis suppurativa severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Patient-reported Numerical Rating Scale (NRS) for pain related to hidradenitis suppurativa | Patient-reported assessment of hidradenitis suppurativa-related pain on a numerical rating scale from 0 (no pain) to 10 (worst imaginable pain). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| D012874 | Skin Diseases, Infectious |
| D013492 | Suppuration |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D016575 | Hidradenitis |
| D013543 | Sweat Gland Diseases |